Please find here the latest situation reports and updates
The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.
orientaciones provisionales, primera publicación: 24 de mayo de 2021, actualización: 21 de octubre de 2021, actualización: 15 de marzo de 2022
Временное руководство (Первый выпуск 24 мая 2021 г., Обновлено 21 октября 2021 г., Обновлено 15 марта 2022 г.
This chronology of facts has challenged public health systems worldwide and regulatory bodies are no exception. Regulatory authorities with mechanisms in place to authorize the use of investigational products had to development guidelines and procedures, create task forces and alliances to maximize ...the efficiency of assessment, review and authorizations of medical products. Vaccines are undoubtedly the most complex medical products to develop, from concept to a stage where sufficient evidence of quality, safety and efficacy are collected to provide an assurance that their use will provide more benefits than risks when used in the context of a public health emergency.
more
20 April 2022. The response to the COVID-19 pandemic continues to adversely affect essential TB services in many countries. A first report of case studies was published in 2021 comprising 23 examples of innovative interventions implemented by countries to effectively respond to disruptions of TB ser...vices caused or exacerbated by the COVID-19 pandemic. This second, consolidated report incorporates new case studies, as well as updates to previously reported case studies
more
A comprehensive view of global deaths directly and indirectly associated with the COVID-19 pandemic.
The monitoring of excess mortality provides us with a more comprehensive understanding of the impact of COVID-19 beyond the number of COVID-19 deaths reported by countries. The World Health Organiza...tion (WHO) is tracking global excess mortality as the pandemic evolves over time to reveal a picture of its full impact and burden on countries, health systems and individuals.
more
May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... the WHO and the PAHO recommend the use of corticosteroids, tocilizumab, baricitinib, and casirivimab e imdevimab (the latter in seronegative COVID-19 patients) and propose the use of sotrovimab, casirivimab/imdevimab, and molnupiravir in patients with non-severe illness who are at high risk for complications
more
Se estima que unos 10 millones de personas contrajeron tuberculosis (TB) en el 2019 y que a unos 3 millones de ellas no se les diagnosticó ni se les notificó la enfermedad. Con el propósito de poner fin a la epidemia mundial de la tuberculosis para el 2030, sigue siendo necesario ampliar la capac...idad para analizar un gran número de muestras.
more
Any individual that meets the suspected case definition of monkeypox should be offered testing in appropriately equipped laboratories by staff trained in the relevant technical and safety procedures. Confirmation of monkeypox virus infection is based on nucleic acid amplification testing (NAAT), usi...ng real-time or conventional polymerase chain reaction (PCR), for detection of unique sequences of viral DNA. PCR can be used alone, or in combination with sequencing. The recommended specimen type for laboratory confirmation of monkeypox is skin lesion material, including swabs of lesion surface and/or exudate, roofs from more than one lesion, or lesion crusts.
more
Fact Sheet about Monkeypox
in English, Arabic, Russian, French, Spanish, Chinese